Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Solstice Biologics LLC

Latest From Solstice Biologics LLC

Start-Up Execs On The Move, July 2014

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Medical Device BioPharmaceutical

Biopharma Dealmaking Quarterly Statistics, Q1 2013

Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009. The $5.5 billion potential deal value aggregate for alliances more than doubled from the previous quarter, mainly due to Biogen Idec’s $3.25 billion buy of Elan's share of multiple sclerosis drug Tysabri.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q1 2013

Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.

BioPharmaceutical Medical Device

Start-Up Execs On The Move, February 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Solstice Biologics LLC
  • Senior Management
  • Corey Goodman, PhD, Pres. & CEO
    John Borgeson, CFO
    Curt Bradshaw, PhD, CSO
  • Contact Info
  • Solstice Biologics LLC
    Phone: (415) 800-0800
    9535 Waples St
    Suite 100
    San Diego, CA 92121